Navigation Links
EpiCept Announces Reverse Stock Split and Change of Corporate Name to Immune Pharmaceuticals Inc.
Date:8/19/2013

4C101, in effect at the start of trading on Wednesday, August 21, 2013.

"The milestones we have achieved today represent the penultimate step in our merger with Immune Pharmaceuticals Ltd.," stated Robert Cook, Interim President and CEO of EpiCept.  "We anticipate that we will formally complete the  merger by the end of the week, at which time we will become Immune Pharmaceuticals Inc."

The 1-for-40 reverse stock split will automatically convert every forty outstanding pre-split shares of the Company's common stock into one outstanding new post-split share of common stock of the re-named Company, Immune Pharmaceuticals Inc.  If the number of shares held by a particular stockholder is not evenly divisible by the ratio of the reverse split, the stockholder's new share count will be rounded up to the nearest whole share.  The reverse split and change of name were authorized by the Company's stockholders on August 6, 2013.  The reverse split will reduce the number of outstanding shares of common stock from 110,252,876 (excluding those shares owned by Immune Pharmaceuticals Ltd.) to 2,756,322, plus those additional shares issued as a result of rounding up.  Upon completion of the merger between the companies, the total outstanding shares of the re-named Company, Immune Pharmaceuticals Inc., will be approximately 12.6 million.

The number of shares of common stock subject to outstanding stock options, stock warrants or convertible securities, and the exercise prices and conversion ratios of those securities, will automatically be proportionately adjusted for the 1-for-40 ratio provided for by the reverse stock split.

In order to effectuate the reverse stock split and change of corporate name, a Certificate of Amendment to EpiCept's Third Amended and Restated Certificate of Incorporation was filed in Delaware on Thursday, August 15, 2013, and will become
'/>"/>

SOURCE EpiCept Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. EpiCept Reports Second Quarter 2013 Operating and Financial Results
2. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
3. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
4. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
5. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
6. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
7. WuXi PharmaTech Announces Third-Quarter 2011 Results
8. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
9. Spherix Announces Third Quarter Financial Results
10. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
11. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014 New test innovations ... in vitro diagnostic (IVD) test industry, especially as companies ... market researcher listed more than 25 testing innovations in ... the future of IVD products. Kalorama details the new approaches ... Worldwide Market for In Vitro Diagnostic Tests , ...
(Date:10/22/2014)... The Americas Inorganic Refrigerants Market report defines ... with analysis and forecast of revenue. , Browse ... Market report, to get an idea of the ... of the segmentation in the Americas inorganic refrigerants ... figures. , http://www.micromarketmonitor.com/market/americas-inorganic-refrigerants-4191654241.html , Inorganic ...
(Date:10/22/2014)... Massachusetts (PRWEB) October 22, 2014 ... announced the release of a new infographic, Understanding ... to create a beautifully designed, easy to follow informative ... transmission, areas of outbreak, symptoms and prevention. , "As ... discovered that the 2014 Ebola outbreak represents not only ...
(Date:10/22/2014)... Ras Al Khaimah, UAE (PRWEB) October 22, 2014 ... in game-changing life science and healthcare projects, announces the ... MBBS MRCGP DRCOG DCH to its advisory team. Dr. ... research advisory team. , A graduate of ... Dr. Siddiqui was subsequently degreed in medicine in 2001. ...
Breaking Biology Technology:Report: Radical New IVD Test Approaches Key To Growth 2Report: Radical New IVD Test Approaches Key To Growth 3The Americas Inorganic Refrigerants Market is estimated to grow to $71.6 million by 2018 - New Report by MicroMarket Monitor 2The Americas Inorganic Refrigerants Market is estimated to grow to $71.6 million by 2018 - New Report by MicroMarket Monitor 3Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2Dr. Yousef Siddiqui joins the Grace Century Advisory Team 2
... LEUVEN, Belgium and LUND, Sweden, September 7 ... Anticoagulant Into Phase,II Clinical Development ThromboGenics NV ... disease, and co-development partner, BioInvent,International (Nordic Exchange: BINV), ... initial follow-up of all volunteers,in the first Phase ...
... 6 Globally, approximately 418 billion,people are currently ... costs of hepatitis in the 21st century cannot ... a,new report by Kalorama Information. Paradoxically, despite ... necessary steps to contain hepatitis. Yet the incidence ...
... VRUS ) and Roche (OTC: RHHBY) announced ... the treatment of chronic hepatitis C,virus (HCV) will ... Hepatitis C,Virus and Related Viruses being held from ... of PSI-6130, is an oral cytidine nucleoside,analog polymerase ...
Cached Biology Technology:ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402 2ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402 3ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402 4ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402 5Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health 2Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses 2Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses 3Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses 4Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses 5
(Date:10/16/2014)... have a new synthesis of recent research findings to ... in the two states. , The Ecology and ... Washington: A Synthesis of the Relevant Biophysical Science and ... published by the U.S. Forest Service,s Pacific Northwest Research ... managers for a synthesis of the large body of ...
(Date:10/16/2014)... NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market announces ... the Smart Wallet, at the 13 th annual ... global conference on the intersection of technology and the ... , founder and publisher of the Strategic News Service™, ...
(Date:10/15/2014)... is spreading rapidly and to an unexpected extent. The ... past and the virus shows a new disease dynamic ... For this reason, the German National Academy of Sciences ... Engineering, and the Union of the German Academies of ... Ebola epidemic today. , In the statement the academies ...
Breaking Biology News(10 mins):New report synthesizes best available science on management of moist mixed-conifer forests 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3Academies call for consequences from the Ebola virus epidemic 2Academies call for consequences from the Ebola virus epidemic 3Academies call for consequences from the Ebola virus epidemic 4Academies call for consequences from the Ebola virus epidemic 5
... Researchers at National Jewish Health have discovered ... infected immune cells to sabotage their own defensive ... and suggest potential therapeutic targets for food poisoning, ... issue of the Journal of Experimental Medicine ...
... are usually the domain of forensic scientists, but palaeontologists ... on our earliest ancestry. The researchers, from ... devised a new method for extracting information from 500 ... decompose to gain a clearer picture of how our ...
... strategy for conserving and restoring damaged ecosystems, and using ... these systems. But what are the risks involved ... near the damaged site? Introduced populations often hybridize ... can result in "polluting" neighboring populations with genes that ...
Cached Biology News:National Jewish Health researchers discover how virulent bacteria 2Novel studies of decomposition shed new light on our earliest fossil ancestry 2Are new genes always better? 2
... 384-well reaction module is used for nucleic ... with an interchangeable, 384-well reaction module (5-20 ... and control and ramp rates that are ... the iCycler base with 384-well reaction module, ...
... Engine instrument is the cycler that ... thermal uniformity and swappable blocks ensure ... This rugged machine is more ... platform for new features and upgrades ...
... The Gene Pulser Xcell microbial system, ... is used for electroporation of bacterial ... the main unit, PC module for ... 10 sterile cuvettes (5 each of ...
... and endothelial cells-directed transfection reagent ... peptide-conjugated polyethylenimine which allows targeted ... and endothelial cells. Integrins are ... and cell-matrix adhesion processes. Many ...
Biology Products: